AVIV THERAPEUTICS
Innovation that will transform access to advanced treatments in Latin America
A problem,
accessibility
New advanced medicines are saving lives of patients with serious illnesses.
​
South America faces a critical challenge in accessing many of these therapies, due to their high cost, limited infrastructure and lack of specialized centers for their manufacture and administration. One day, these drugs could cure millions of people suffering from cancer, HIV, genetic diseases and other serious disorders.
​
AVIV focuses on CAR-T therapies, which are highly effective against certain hematological cancers but inaccessible to most due to high costs and dependence on imports, exacerbating inequalities in life-saving treatments.
The solution we propose
Our mission is to manufacture accessible CAR-T therapies in Uruguay and South America, improving cancer treatment in low-income regions. We forge strategic alliances and collaborate with hospitals to produce point-of-care therapies, reducing costs by avoiding the complex logistics of centralized manufacturing. With research, partnerships, and a focus on the patient, we seek to lead in medical innovation and provide transformative solutions.
Through national and international collaborations
Aviv Therapeutics transforms access to innovative therapies in Uruguay by sponsoring CAR-T clinical trials through strategic alliances with national public health centers, together with the support and collaboration of reference centers worldwide, adopting a non-profit approach. This strategic alliance allows the transfer of cutting-edge technology and ensures international quality standards.
The project marks a milestone for patients to access disruptive treatments without economic barriers, strengthening local capacity and collaborating with public and international institutions. Aviv seeks to impact the quality of life of patients and position Uruguay as a leader in biotechnology in South America.
How are we going to achieve this?
Our vision
To give patients in South America access to accessible and affordable CAR-T cell therapies, bringing curative solutions to people who need them. This initiative will be developed under a non-profit model. Our goal is to transform the treatment landscape for cancer and other critical health conditions in low-income regions, where access to advanced therapies, and in particular those that need to be manufactured locally or regionally to be most effective, remains a challenge.
CAR-T therapies
What are they about?
CAR-T therapies are an innovative immunotherapy that uses the patient's own T cells to fight cancer. It involves harvesting them, genetically modifying them to recognize and attack specific cancer cells, and reintroducing them into the body. These cells multiply and destroy tumor cells with high precision.
Why are they effective?
CAR-T therapies are highly effective, specifically targeting tumor cells and minimizing damage to healthy cells. Thanks to personalized chimeric receptors, they identify molecules in cancer cells and have achieved high remission rates in advanced or refractory hematological cancers.
Second line of treatment
CAR-T therapies are becoming established as second-line therapies for hematological cancers such as B-cell lymphoma and acute lymphoblastic leukemia, in patients who do not respond to initial treatments. Their efficacy in critical stages is clear, but factors such as high cost and production complexity limit their adoption, highlighting the need to make them more accessible in regions with fewer resources.
The transformative potential of CAR-T therapies
The scope of CAR-T therapies transcends the treatment of hematological cancers, with ongoing research to address solid tumors, a complex challenge due to the characteristics of the tumor microenvironment. In addition, clinical trials are exploring their potential in infectious diseases such as HIV, seeking to eradicate viral reservoirs, and in autoimmune disorders such as lupus and multiple sclerosis. Applications in genetic diseases are also being evaluated, taking advantage of the ability of CAR-T cells to redirect and modulate the immune system. These advances promise to expand the impact of this revolutionary technology to a wide range of complex pathologies.
Experience and scientific knowledge
Potential for Uruguay and South America
Impact on health and scientific knowledge
Manufacturing CAR-T therapies and conducting clinical trials in Uruguay and South America will not only save lives by offering cutting-edge treatments to local patients, but will also boost the development of scientific expertise and knowledge in the region. This advance will strengthen the local scientific-technological ecosystem, creating a solid foundation for future research and development (R&D) projects and the production of innovative new therapies.
Decentralized access to advanced therapies
A decentralized system would allow patients to access these therapies at their point of care, bringing the technology closer to those who need it most. This approach reduces geographic and economic barriers, increasing equity in access to transformative treatments.
Challenges and benefits of the proposed model
While this model presents major challenges in infrastructure and financing, its benefits are immense. From promoting greater equity in access to positioning the region as a leader in biotechnology and advanced medicine, this effort represents a unique opportunity to transform the health landscape in South America.
Our team
Vision. Dedication. Experience. Passion.
We are a team of passionate entrepreneurs and scientists, united by a clear and ambitious vision: to make history in Uruguay by providing access to disruptive, innovative and effective treatments for dozens of patients each year.
